Medical Oncology

Viral Hepatitis

Questions discussed in this category

Would you consider starting immunotherapy in a patient with stage IV NSCLC, a high PDL1 level, and active, untreated hepatitis C?

1 Answer available

Are you routinely using thrombopoietin agonists in patients with hep C and HCC?

If so, for what platelet count threshold and do you have a preference as to which agent?

1 Answer available

How do you sequence antiviral therapy and cancer-directed therapy in a newly diagnosed patient with hepatocellular carcinoma and incidentally found hepatitis C?

Is there a "best" way to approach treatment of the viral infection i.e concurrently with therapy, prior to therapy, delayed or post therapy? Does this...

1 Answer available

Papers discussed in this category

J. Hepatol., 2019 Apr 06

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.

Gastroenterology, 2018 May 17

Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.

Clin. Gastroenterol. Hepatol., 2018 Nov 28

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.

Hepatology (Baltimore, Md.), 2019-10

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).

Am J Gastroenterol, 2023 Sep 1

Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.

The oncologist, 2021 Mar 20

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.

Medicine, 2020 Jan

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.

Medical Oncology

Viral Hepatitis

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology